Steadfast in their commitment to harness the power of nitric oxide, Beyond Air (former AIT) are revolutionizing care to transform patients lives. The combined product of drug and device is a revolutionary respiratory targeted system designed to safely and effectively deliver of NO (Nitric Oxide) to non-intubated patients (home or hospital) in order to treat severe lung infections, including bronchiolitis and cystic fibrosis. The company conducted several Phase 2 trials. Improvement in oxygenation, significant reduction of time to discharge and reduction of bacterial loads were observed.